New phase 3b trial results show Lilly’s Trulicity combined with an SGLT2 inhibitor failed to show any benefits above and beyond Trulicity’s blood glucose lowering.
Novo Nordisk must up its bid to take over Belgian biotech Ablynx, after the company’s largest shareholder reportedly said its 2.6 billion euro ($3.18 billion) offer was too low.